EXTON, Pa. -- (BUSINESS WIRE) -- Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer, and Greg Weaver, senior vice president and chief financial officer, of Fibrocell Science will present at the Wedbush 2014 Life Sciences Management Access Conference at 10:20 a.m. EDT on Tuesday, August 12, 2014, in New York City. Mr. Pernock and Mr. Weaver will discuss the company’s autologous fibroblast technology, its therapeutic candidates in development, and its collaboration with Intrexon Corporation (NYSE: XON) to develop genetically-modified personalized biologics.
A live webcast of the presentation will be available on Fibrocell's website at http://www.fibrocellscience.com/investors/events-and-presentations/. The presentation will be archived on the company's website and available for 30 days.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Based on its proprietary autologous fibroblast technology, Fibrocell is pursuing breakthrough medical applications of azficel-T for restrictive burn scarring and vocal cord scarring. The company’s collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, includes using genetically-modified fibroblasts for treating orphan skin diseases for which there are no currently approved products. For additional information, visit www.fibrocellscience.com.